title: Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
abstract: The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.
authors: Galveston National Laboratory, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77550-0610, USA. tom.geisbert@utmb.edu
authors: Thomas W
authors: TW
authors: Geisbert
authors: Heinz
authors: H
authors: Feldmann
mesh_terms: D000818:Animals; D029043:Ebolavirus / Q000145:classification / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000517:prevention & control* / Q000821:virology; D008379:Marburg Virus Disease / Q000517:prevention & control*; D029024:Marburgvirus / Q000276:immunology*; D014614:Vaccines, Synthetic; D018116:Vesiculovirus / Q000235:genetics*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics
chemical_list: D014614:Vaccines, Synthetic; D014765:Viral Vaccines